Lupin Ltd
Lupin Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Lupin aims for double-digit growth in revenues and volumes across markets, targeting 20-30% growth ahead of market, where the market grows at 6-8%. Expectation of margin improvement continuously driven by a strong product pipeline and cost efficiency initiatives (Page 21).
From Lupin Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Lupin aims for double-digit growth in revenues and volumes across markets, targeting 20-30% growth ahead of market, where the market grows at 6-8%. (Page 28)
- India business targets 1.2-1.3 times market growth with double-digit growth driven by chronic therapies, new product launches, and expanded reach including extra urban markets. (Pages 13, 29)
- Continued robust growth expected in complex generics and specialty, particularly in the US and Developed Markets, leveraging a strong product pipeline and new launches like Tolvaptan, Mirabegron, and Spiriva®. (Pages 21, 31)
- Growth in biosimilars, injectables, respiratory, oncology, and GI therapy areas projected. (Pages 10, 13, 31)
2 more points from Lupin Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Lupin Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Annual capital expenditure has averaged INR 500-700 crores over the last 4-5 years, mainly for maintenance capex and some expansion in biosimilars, injectables, and related areas. (Ramesh Swaminathan, p.31)
- FY25 capex shown as INR 1600 crores includes acquisitions and intangibles (e.g., Medisol acquisition). Cash flow capex figure is after accounting for these. (Ramesh Swaminathan, p.31)
- Future capital allocation focuses on specialty and India regions with strict guardrails: Debt to EBITDA around 2:1, expected return around 20%, and payback period between 4-6 years per project. (Ramesh Swaminathan, p.28-29)
2 more points from Lupin Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lupin Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Lupin has more than 100 products pending in the pipeline for approval in the US market.
- The pending pipeline addresses a market size of close to USD 150 billion.
- Key recent approvals include Mirabegron, Spiriva®, Pred Forte®, and Tolvaptan, indicating strong momentum.
- CDMO/CRDMO business is evolving with additional capacity available, and the company is building a commercial and project management team to scale this.
2 more points from Lupin Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Lupin Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹1.5K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lupin Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Lupin Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lupin Ltd Q4 FY25 results?
Lupin aims for double-digit growth in revenues and volumes across markets, targeting 20-30% growth ahead of market, where the market grows at 6-8%. Expectation of margin improvement continuously driven by a strong product pipeline and cost efficiency initiatives (Page 21).
What is Lupin Ltd share price analysis?
Lupin Ltd currently shows a neutral. The stock trades at a P/E of 17.2 with a market cap of ₹102,191 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lupin Ltd planning capital expenditure?
Annual capital expenditure has averaged INR 500-700 crores over the last 4-5 years, mainly for maintenance capex and some expansion in biosimilars, injectables, and related areas.
Keep Lupin Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.